Lantern Pharma Inc.
LTRN
$3.16
-$0.03-0.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 22.78% | -30.39% | 9.15% | 8.85% | -29.98% |
| Total Depreciation and Amortization | 2.34% | 6.89% | 3.46% | 1,029.27% | -97.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -92.63% | 356.50% | -968.18% | -89.81% | 197.74% |
| Change in Net Operating Assets | -94.74% | 243.64% | -203.15% | -114.15% | 142.36% |
| Cash from Operations | -10.17% | 28.85% | -7.55% | -69.16% | 9.36% |
| Capital Expenditure | 61.29% | -3.33% | 30.23% | -95.45% | 56.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.08% | 404.87% | 445.50% | 64.30% | -312.02% |
| Cash from Investing | -6.03% | 406.73% | 436.62% | 63.66% | -317.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | -- | -100.00% | 110.94% |
| Foreign Exchange rate Adjustments | 104.17% | -514.81% | 43.36% | 215.31% | -104.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.57% | 87.86% | 9.43% | -50.33% | 1.49% |